- Home
- TMUS vs ABBV Comparison
TMUS vs ABBV Comparison
Compare TMUS & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMUS | ABBV |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5B | 358.5B |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TMUS | ABBV |
|---|---|---|
| Price | $183.60 | $233.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | ★ $256.65 | $253.71 |
| AVG Volume (30 Days) | ★ 5.1M | 3.9M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | 2.06% | ★ 3.39% |
| EPS Growth | ★ 0.62 | N/A |
| EPS | ★ 2.27 | 0.39 |
| Revenue | $40,604,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $9.27 | $11.87 |
| Revenue Next Year | $4.59 | $8.12 |
| P/E Ratio | ★ $81.30 | $601.87 |
| Revenue Growth | ★ 9.03 | 8.57 |
| 52 Week Low | $174.02 | $181.75 |
| 52 Week High | $261.50 | $244.81 |
Technical Indicators
Market Signals| Indicator | TMUS | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 63.96 |
| Support Level | $174.02 | $220.11 |
| Resistance Level | $200.87 | $237.81 |
| Average True Range (ATR) | 5.22 | 5.27 |
| MACD | 0.28 | 0.74 |
| Stochastic Oscillator | 56.33 | 83.99 |
Price Performance
Historical ComparisonAbout TMUS T-Mobile US Inc.
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the US. T-Mobile now serves about 86 million postpaid and 26 million prepaid phone customers, equal to around 30% of the US retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves 8 million residential and business customers with its wireless network. It also serves 1 million fiber broadband customers through joint ventures with fiber network owners. T-Mobile owns a stake in these firms, which provide wholesale access to their networks. In addition, T-Mobile provides wholesale services to wireless resellers.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.